SEC Form D raise Raised $29.44M in debt securities (Form D filed Oct 23, 2025); 1 role open. SEC Form D 0000905148-25-003655 (Oct 23, 2025)Evidence (1 event)
Oct 23, 2025 · SEC Form D 0000905148-25-003655 Name of Issuer: RECODE THERAPEUTICS, INC.; CIK: 1693764; Address: city not listed;Brien Drive, Menlo Park, CALIFORNIA; Submission type: D; Filing date: 2025-10-23; Industry Group: Biotechnology; Date of First Sale: 2025-09-23; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 29441931; Total Amount Sold: 29441931; Federal exemptions: 06b
Trial start Phase 1: Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance source ↗
Trial start Phase 1: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD source ↗
Trial start 2: A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF source ↗
Trial start —: A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials source ↗
Trial start —: A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults source ↗
Trial start Phase 1: Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects source ↗
Upcoming milestones
2026-11 (ESTIMATED) · 2 · A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF · NCT06237335
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
